RECEPTOR ANTAGONISTS CANNABINOID-1 IN DIABETES TYPE 2
Type 2 diabetes is closely related to abdominal obesity and is generally associated with other cardiometabolic risk factors, resulting in a risk of major cardiovascular disease. In human central and peripheral endocannabinoid actions, via the activation of Cb1 receptor, promote weight gain and associated metabolic changes. Rimonabant, the first selective CB (1) receptor blocker to reduce body weight, waist circumference, triglycerides, blood pressure, insulin resistance index and C-reactive protein levels, and to increase high-density lipoprotein (HDL) cholesterol and adiponectin conecentrations in both non-diabetic and diabetic overweight/obse patients. A 0.5-0.7 % reduction in HbA1c levels was observed in metformin- or sulphonylurea-treated patients with type-2 diabetes and in drug-native diabetic patients. Almost half of the metabolic changes, including HbA1c reduction, could not be explained by weight loss, sugesting that there aredirect peripheral effects. Rimonabant was generally well-tolerated, and the safety profile was similar in diabetic and non-diabetic patients, with a higher incidence of depressed nood disorders, nausea and dizziness. The potential role of rimonabant in over weight/obse patients with type-2 diabetes and at hight risk of cardiovascular disease deserves much consideration
Type 2 diabetes is closely related to abdominal obesity and is generally associated with other cardiometabolic risk factors, resulting in a risk of major cardiovascular disease. In human central and peripheral endocannabinoid actions, via the activation of Cb1 receptor, promote weight gain and associated metabolic changes. Rimonabant, the first selective CB (1) receptor blocker to reduce body weight, waist circumference, triglycerides, blood pressure, insulin resistance index and C-reactive protein levels, and to increase high-density lipoprotein (HDL) cholesterol and adiponectin conecentrations in both non-diabetic and diabetic overweight/obse patients. A 0.5-0.7 % reduction in HbA1c levels was observed in metformin- or sulphonylurea-treated patients with type-2 diabetes and in drug-native diabetic patients. Almost half of the metabolic changes, including HbA1c reduction, could not be explained by weight loss, sugesting that there aredirect peripheral effects. Rimonabant was generally well-tolerated, and the safety profile was similar in diabetic and non-diabetic patients, with a higher incidence of depressed nood disorders, nausea and dizziness. The potential role of rimonabant in over weight/obse patients with type-2 diabetes and at hight risk of cardiovascular disease deserves much consideration
No comments:
Post a Comment